Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam.Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2—9, F41.1—9, F45.0—1 by ICD-10) were examined.Results. Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a week after last receiving the peptide. Selank had a positive impact on the quality of life of the patients.Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders. © 2014, Media Sphera. All rights reserved.